Pancreatic Cancer Precision Medicine Market Report 2026

Pancreatic Cancer Precision Medicine Market Overview

• Pancreatic Cancer Precision Medicine market size has reached to $0.58 billion in 2025 • Expected to grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 16.6% • Growth Driver: Rising Prevalence Of Pancreatic Cancer Fueling The Growth Of The Market Due To Increasing Demand For Personalized And Targeted Therapies • Market Trend: Revolutionizing Pancreatic Cancer Treatment With AI-Driven Precision Tool And Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pancreatic Cancer Precision Medicine Market?

Pancreatic cancer precision medicine is a specialized treatment strategy that focuses on personalizing care for pancreatic cancer patients. It relies on genetic and molecular information from the patient and their cancer to create a customized treatment plan. Pancreatic cancer precision medicine improves patient outcomes by personalizing treatment, reducing unnecessary treatments, and increasing the chances of successful interventions. The main therapeutic approach in pancreatic cancer precision medicine are targeted therapy, immunotherapy, chemotherapy-precision combinations, and others. Targeted therapy specifically uses drugs designed to address genetic mutations, proteins, or other molecules that drive the growth and spread of cancer cells. A range of diagnostic technologies supports these treatments, including genomic testing, molecular diagnostics, liquid biopsy, biomarker-based companion diagnostics, and others. These technologies and therapies are applied across various settings such as hospitals, specialty clinics, academic and research institutes, and diagnostic centers.

What Is The Pancreatic Cancer Precision Medicine Market Growth Forecast?

The pancreatic cancer precision medicine market size is expected to see rapid growth in the next few years. It will grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to growth in precision oncology adoption, rising investment in pancreatic cancer research, advancements in diagnostic technologies, expansion of immunotherapy pipelines, increasing use of companion diagnostics. Major trends in the forecast period include increasing use of genomic and molecular profiling, growing adoption of biomarker-based therapies, expansion of targeted and immunotherapy combinations, rising use of liquid biopsy diagnostics, increasing focus on personalized treatment pathways.

Global Pancreatic Cancer Precision Medicine Market Segmentation

1) By Therapeutic Approach: Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approaches 2) By Diagnostic Technology: Genomic Testing, Molecular Diagnostics, Liquid Biopsy, Biomarker-Based Companion Diagnostics, Other Diagnostic Technologies 3) By Application: Hospitals, Specialty Clinics, Academic And Research Institutes, Diagnostic Centers Subsegments: 1) By Targeted Therapy: Kinase Inhibitors, PARP Inhibitors 2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy 3) By Chemotherapy-Precision Combinations: Gemcitabine-Based Combinations, Fluorouracil-Based Combinations, Nab-Paclitaxel-Based Combinations 4) By Other Therapeutic Approaches: RNA-Based Therapies, Epigenetic Modulators, Antibody-Drug Conjugates (ADCs)

What Is The Driver Of The Pancreatic Cancer Precision Medicine Market?

The rising prevalence of pancreatic cancer is expected to propel the growth of the pancreatic cancer precision medicine market going forward. Pancreatic cancer is a type of cancer that begins in the tissues of the pancreas, an organ essential for digestion and blood sugar regulation. The pancreatic cancer incidence is rising due to the aging population combined with the growing prevalence of risk factors such as obesity, diabetes, and smoking. Pancreatic cancer precision medicine enhances cancer management by offering personalized treatment plans based on genetic and molecular information. It improves treatment effectiveness and reduces side effects, making it a crucial tool in managing pancreatic cancer more efficiently. For instance, in February 2025, according to Cancer Australia, an Australia-based government agency, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. Therefore, the rising prevalence of pancreatic cancer is driving the growth of the pancreatic cancer precision medicine industry.

Key Players In The Global Pancreatic Cancer Precision Medicine Market

Major companies operating in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Amgen Inc., Eli Lilly and Company, Genentech Inc., Ipsen Pharma, Bayer AG, Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health, Foundation Medicine Inc., Oncolytics Biotech Inc., Erytech Pharma, PharmaCyte Biotech Inc., Celgene Corporation, Natera Inc.

Global Pancreatic Cancer Precision Medicine Market Trends and Insights

Major companies operating in the pancreatic cancer precision medicine market are focusing on developing advanced technologies, such as precision medical tool, to enhance early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for improved patient outcomes. A precision medical tool is a specialized device that helps diagnose and treat diseases accurately based on a person’s unique biology. For instance, in January 2024, Cedars-Sinai, a US-based hospital and healthcare company, launched molecular twin precision oncology platform, precision medical tool to better predict pancreatic cancer survival by identifying key biomarkers. The platform's strong potential lies in guiding treatment decisions, even in areas with limited resources, by using blood and tissue samples from 74 patients with pancreatic ductal adenocarcinoma to offer a more accurate and accessible approach to precision oncology.

What Are Latest Mergers And Acquisitions In The Pancreatic Cancer Precision Medicine Market?

In January 2024, Bristol Myers Squibb, a US–based biopharmaceutical company that develops and commercializes innovative medicines across oncology, immunology, cardiovascular and other therapeutic areas, acquired Mirati Therapeutics for an undisclosed amount. With this acquisition, Bristol Myers Squibb gains access to Mirati’s targeted oncology assets, including the commercial KRAS G12C inhibitor Krazati (adagrasib) and a complementary pipeline of KRAS- and PRMT5-focused programs, thereby expanding its precision oncology capabilities while strengthening its global oncology portfolio. Mirati Therapeutics is a US–based commercial-stage biotechnology company that specializes in targeted cancer therapeutics and is known for its deep expertise in developing precision oncology programs for KRAS-mutant cancers.

Regional Insights

North America was the largest region in the pancreatic cancer precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pancreatic Cancer Precision Medicine Market?

The pancreatic cancer precision medicine market includes revenues earned by entities by providing services such as personalized treatment planning, tumour molecular profiling, precision imaging and diagnostics, and targeted therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic cancer precision medicine market consists of sales of genetic and biomarker testing kits, immunotherapy drugs, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pancreatic Cancer Precision Medicine Market Report 2026?

The pancreatic cancer precision medicine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer precision medicine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.